{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:27:23Z","timestamp":1787808443340,"version":"build-2784847793"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and is characterized by the progressive growth of multiple kidney cysts, leading to kidney failure in most patients. The management of ADPKD, which up to a decade ago was limited to supportive measures to preserve kidney function and prevent complications, has evolved with the regulatory approval of disease-modifying agents. This review provided an overview of the current status and future perspectives of treatment for ADPKD. At present, the only drugs approved to slow disease progression are the vasopressin V2-receptor antagonist tolvaptan and, in Italy, the somatostatin analog octreotide long-acting release for the subset of patients with stage 4 CKD. However, various therapeutic strategies are under clinical investigation. These include not only repurposed pharmacological agents, namely sodium-glucose cotransporter-2 inhibitors, metformin, and glucagon-like peptide-1 receptor agonists, but also innovative therapies which is the case for a monoclonal antibody against pregnancy-associated plasma protein-A, microRNA-17 inhibitors, and the polycystin-1 correcting agent VX-407. Dietary interventions, such as caloric restriction and ketogenic diets, are being tested in clinical trials as well and could complement pharmacotherapy to slow disease progression. Moreover, the rapid advancements in the field of gene therapy for ADPKD suggest that this approach, though as yet only explored at experimental level, could be translated into clinical practice in future to correct the underlying genetic defect, and potentially reverse disease pathogenesis, thereby improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000975","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:01:44Z","timestamp":1764954104000},"page":"1445-1455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care"],"prefix":"10.2215","volume":"21","author":[{"given":"Monica","family":"Cortinovis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-4327","authenticated-orcid":false,"given":"Norberto","family":"Perico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3446","authenticated-orcid":false,"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"8","key":"B1-20260826","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B2-20260826","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney Dis (Basel)."},{"issue":"24","key":"B3-20260826","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1001\/jama.2022.22847","article-title":"Exome sequencing of a clinical population for autosomal dominant polycystic kidney disease","volume":"328","author":"Chang","year":"2022","journal-title":"JAMA."},{"issue":"12","key":"B4-20260826","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.34067\/KID.0004522021","article-title":"Autosomal dominant polycystic kidney disease prevalence among a racially diverse United States population, 2002 through 2018","volume":"2","author":"Aung","year":"2021","journal-title":"Kidney360."},{"issue":"1","key":"B5-20260826","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B6-20260826","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers."},{"issue":"19","key":"B7-20260826","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2025.0310","article-title":"Autosomal dominant polycystic kidney disease: a review","volume":"333","author":"Chebib","year":"2025","journal-title":"JAMA."},{"issue":"7","key":"B8-20260826","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ekir.2019.04.018","article-title":"Intrafamilial variability of ADPKD","volume":"4","author":"Lanktree","year":"2019","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B9-20260826","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B10-20260826","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"15","key":"B11-20260826","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.3390\/jcm12155133","article-title":"Abdominal imaging in ADPKD: beyond total kidney volume","volume":"12","author":"Caroli","year":"2023","journal-title":"J Clin Med."},{"issue":"9","key":"B12-20260826","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1007\/s00330-023-09601-4","article-title":"Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD","volume":"33","author":"Caroli","year":"2023","journal-title":"Eur Radiol."},{"issue":"5","key":"B13-20260826","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2215\/CJN.0000000680","article-title":"Predicting kidney outcomes in autosomal dominant polycystic kidney disease: a comprehensive biomarker analysis","volume":"20","author":"Bais","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B14-20260826","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int."},{"issue":"4","key":"B15-20260826","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B16-20260826","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int."},{"issue":"25","key":"B17-20260826","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med."},{"issue":"20","key":"B18-20260826","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"B19-20260826","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ekir.2021.11.034","article-title":"Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD","volume":"7","author":"Higashihara","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"4","key":"B20-20260826","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3390\/ijms25042088","article-title":"Long-term effects of tolvaptan in autosomal dominant polycystic kidney disease: predictors of treatment response and safety over 6 years of continuous therapy","volume":"25","author":"Yamazaki","year":"2024","journal-title":"Int J Mol Sci."},{"issue":"5","key":"B21-20260826","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.xkme.2025.100988","article-title":"Effectiveness of tolvaptan for autosomal dominant polycystic kidney disease in US clinical practice with comparison to historical control data","volume":"7","author":"Perrone","year":"2025","journal-title":"Kidney Med."},{"issue":"9","key":"B22-20260826","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/ndt\/gfaf048","article-title":"The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD","volume":"40","author":"Geertsema","year":"2025","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B23-20260826","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12882-021-02607-4","article-title":"Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN\u00ae dataset","volume":"22","author":"Thomas","year":"2021","journal-title":"BMC Nephrol."},{"issue":"11S","key":"B24-20260826","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1681\/ASN.20233411S1209a","article-title":"Eight years of Canadian real-world assessment of tolvaptan in ADPKD: C-MAJOR study and safety monitoring and distribution program: TH-PO425","volume":"34","author":"McFarlane","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B25-20260826","doi-asserted-by":"crossref","first-page":"22257","DOI":"10.1038\/s41598-023-48638-9","article-title":"Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort","volume":"13","author":"Calvaruso","year":"2023","journal-title":"Sci Rep."},{"issue":"9","key":"B26-20260826","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.34067\/KID.0000000816","article-title":"Real-world tolvaptan use in autosomal dominant polycystic kidney disease: insights from two US medical centers","volume":"6","author":"Rao","year":"2025","journal-title":"Kidney360."},{"issue":"187","key":"B27-20260826","first-page":"262","volume":"26","year":"2017","journal-title":"Prescrire Int."},{"issue":"3","key":"B28-20260826","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of Tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"B29-20260826","doi-asserted-by":"crossref","first-page":"sfaf062","DOI":"10.1093\/ckj\/sfaf062","article-title":"Five years of post-marketing liver safety data from the tolvaptan risk evaluation and mitigation strategy","volume":"18","author":"Lohrmann","year":"2025","journal-title":"Clin Kidney J."},{"issue":"12","key":"B30-20260826","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v10i12.3232","article-title":"Octreotide Lar in patients with autosomal dominant polycystic kidney disease: from bench to a novel perspective of therapy","volume":"10","author":"Ruggenenti","year":"2022","journal-title":"Med Res Arch."},{"issue":"1","key":"B31-20260826","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int."},{"issue":"9903","key":"B32-20260826","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet."},{"issue":"4","key":"B33-20260826","doi-asserted-by":"crossref","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med."},{"issue":"9","key":"B34-20260826","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s40620-024-02145-w","article-title":"Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience","volume":"37","author":"Riccio","year":"2024","journal-title":"J Nephrol."},{"issue":"19","key":"B35-20260826","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 Randomized Clinical Trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA."},{"issue":"6","key":"B36-20260826","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/0016-5085(95)90157-4","article-title":"Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition","volume":"108","author":"Tan","year":"1995","journal-title":"Gastroenterology"},{"issue":"3","key":"B37-20260826","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1677\/joe.1.06082","article-title":"Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts","volume":"187","author":"Smith","year":"2005","journal-title":"J Endocrinol."},{"key":"B38-20260826","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2018.10.063","article-title":"Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: a cross-sectional and longitudinal substudy of the ALADIN trial","volume":"275","author":"Spinelli","year":"2019","journal-title":"Int J Cardiol."},{"issue":"7","key":"B39-20260826","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"B40-20260826","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B41-20260826","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","article-title":"Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data","volume":"145","author":"Gevers","year":"2013","journal-title":"Gastroenterology."},{"issue":"2","key":"B42-20260826","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"DIPAK-1 investigators: lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease","volume":"157","author":"van Aerts","year":"2019","journal-title":"Gastroenterology."},{"issue":"3","key":"B43-20260826","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","author":"Irazabal","year":"2011","journal-title":"Kidney Int."},{"issue":"6","key":"B44-20260826","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int."},{"issue":"8","key":"B45-20260826","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B46-20260826","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2215\/CJN.0000000000000049","article-title":"Effects of octreotide-long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial","volume":"18","author":"Trillini","year":"2023","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7","key":"B47-20260826","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol."},{"issue":"24","key":"B48-20260826","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"15","key":"B49-20260826","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD trial committees and investigators: dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"2","key":"B50-20260826","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"1","key":"B51-20260826","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol."},{"issue":"4","key":"B52-20260826","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7570\/jomes21061","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis","volume":"30","author":"Cho","year":"2021","journal-title":"J Obes Metab Syndr."},{"issue":"4","key":"B53-20260826","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension."},{"issue":"2","key":"B54-20260826","doi-asserted-by":"crossref","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep."},{"issue":"5","key":"B55-20260826","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int."},{"issue":"6","key":"B56-20260826","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in han: sprd rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res."},{"issue":"4","key":"B57-20260826","doi-asserted-by":"crossref","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"key":"B58-20260826","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine."},{"issue":"7","key":"B59-20260826","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.0000000725","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease","volume":"20","author":"Eswarappa","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B60-20260826","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ekir.2025.01.023","article-title":"Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan","volume":"10","author":"Uchiyama","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"6","key":"B61-20260826","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"B62-20260826","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br J Pharmacol."},{"issue":"1","key":"B63-20260826","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1152\/ajprenal.00298.2021","article-title":"Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model","volume":"322","author":"Pastor-Soler","year":"2022","journal-title":"Am J Physiol Renal Physiol."},{"issue":"10","key":"B64-20260826","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/hmg\/ddab340","article-title":"Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice","volume":"31","author":"Chang","year":"2022","journal-title":"Hum Mol Genet."},{"issue":"3","key":"B65-20260826","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int."},{"issue":"4","key":"B66-20260826","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B67-20260826","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B68-20260826","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2215\/CJN.0000000640","article-title":"Overweight status, obesity, and progression to ESKD in patients with autosomal dominant polycystic kidney disease","volume":"20","author":"Nowak","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"16","key":"B69-20260826","doi-asserted-by":"crossref","first-page":"e70944","DOI":"10.1096\/fj.202501605R","article-title":"GLP-1RA semaglutide delays the progression of ADPKD through regulation of glycolysis, mitochondria function and ketosis","volume":"39","author":"Wu","year":"2025","journal-title":"FASEB J."},{"issue":"4","key":"B70-20260826","doi-asserted-by":"crossref","first-page":"e135700","DOI":"10.1172\/jci.insight.135700","article-title":"Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis","volume":"5","author":"Kashyap","year":"2020","journal-title":"JCI Insight."},{"key":"B71-20260826","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat Commun."},{"issue":"1","key":"B72-20260826","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","article-title":"PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression","volume":"13","author":"Lakhia","year":"2022","journal-title":"Nat Commun."},{"issue":"1","key":"B73-20260826","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun."},{"issue":"10S","key":"B74-20260826","doi-asserted-by":"crossref","first-page":"B23","DOI":"10.1681\/ASN.2024w1ps7ssb","article-title":"RGLS8429: increases urinary PC1 and PC2 and may reduce height-adjusted total kidney volume (htTKV) in patients with ADPKD","volume":"35","author":"Yu","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B75-20260826","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.stem.2024.03.005","article-title":"Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease","volume":"31","author":"Vishy","year":"2024","journal-title":"Cell Stem Cell."},{"issue":"12","key":"B76-20260826","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41588-021-00946-4","article-title":"Renal plasticity revealed through reversal of polycystic kidney disease in mice","volume":"53","author":"Dong","year":"2021","journal-title":"Nat Genet."},{"issue":"1","key":"B77-20260826","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41467-023-37449-1","article-title":"The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion","volume":"14","author":"Onuchic","year":"2023","journal-title":"Nat Commun."},{"issue":"5","key":"B78-20260826","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B79-20260826","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"B80-20260826","doi-asserted-by":"crossref","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2022","journal-title":"iScience."},{"issue":"6","key":"B81-20260826","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"2019","journal-title":"Cell Metab."},{"issue":"11","key":"B82-20260826","doi-asserted-by":"crossref","first-page":"101283","DOI":"10.1016\/j.xcrm.2023.101283","article-title":"Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial","volume":"4","author":"Cukoski","year":"2023","journal-title":"Cell Rep Med."},{"issue":"1","key":"B83-20260826","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/epi4.12370","article-title":"Systematic review of ketogenic diet use in adult patients with status epilepticus","volume":"5","author":"Mahmoud","year":"2020","journal-title":"Epilepsia Open."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:01:09Z","timestamp":1787752869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000975","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}